Harbin Medisan Pharmaceutical Co., Ltd. (SZSE:002900) CEO Jian Fei Qin's Holdings Dropped 13% in Value as a Result of the Recent Pullback
Harbin Medisan Pharmaceutical Co., Ltd. (SZSE:002900) CEO Jian Fei Qin's Holdings Dropped 13% in Value as a Result of the Recent Pullback
Key Insights
主要見解
- Insiders appear to have a vested interest in Harbin Medisan Pharmaceutical's growth, as seen by their sizeable ownership
- A total of 2 investors have a majority stake in the company with 54% ownership
- Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock
- 內部人似乎對哈三聯的發展抱有既定利益,因爲他們持有大量股份
- 該公司的多數股份由2位投資者持有,佔有54%的所有權。
- 所有權研究結合過去的表現數據可以幫助更好地理解股票的機會。
Every investor in Harbin Medisan Pharmaceutical Co., Ltd. (SZSE:002900) should be aware of the most powerful shareholder groups. We can see that individual insiders own the lion's share in the company with 64% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
哈三聯製藥股份有限公司(SZSE:002900)的每個投資者都應知道最強大的股東群體。我們可以看出,個人內部人擁有該公司64%的所有權。也就是說,如果股票上漲(或出現下行趨勢),這個群體將獲益最多(或虧損最多)。
And following last week's 13% decline in share price, insiders suffered the most losses.
上週股價下跌13%,內部人蒙受了最大的損失。
Let's take a closer look to see what the different types of shareholders can tell us about Harbin Medisan Pharmaceutical.
讓我們仔細看看不同類型的股東可以告訴我們哈三聯製藥的什麼情況。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240610/0-ea10006445202d801da1cba1c849a1bc-0-16ca68a24c41001aeac9af00a99109ce.png/big)
What Does The Institutional Ownership Tell Us About Harbin Medisan Pharmaceutical?
機構在哈三聯製藥的持股很少。這表明該公司受到一些基金的關注,但目前並不受專業投資者特別歡迎。如果該公司的收益增長,這可能表明它剛開始吸引這些富有的投資者的注意力。當多家機構投資者想要購買股份時,我們通常會看到股價上漲。以前的營收軌跡(如下所示)可能是未來增長的一種跡象,但並不保證。
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。
Institutions have a very small stake in Harbin Medisan Pharmaceutical. That indicates that the company is on the radar of some funds, but it isn't particularly popular with professional investors at the moment. If the company is growing earnings, that may indicate that it is just beginning to catch the attention of these deep-pocketed investors. When multiple institutional investors want to buy shares, we often see a rising share price. The past revenue trajectory (shown below) can be an indication of future growth, but there are no guarantees.
SZSE:002900營收增長情況2024年6月10日
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240610/0-ea10006445202d801da1cba1c849a1bc-1-0df869991bd2041acb04d820c9a111e4.png/big)
Hedge funds don't have many shares in Harbin Medisan Pharmaceutical. With a 42% stake, CEO Jian Fei Qin is the largest shareholder. In comparison, the second and third largest shareholders hold about 12% and 8.7% of the stock. Interestingly, the third-largest shareholder, Guomin Zhuge is also a Vice Chairman, again, indicating strong insider ownership amongst the company's top shareholders.
哈三聯製藥的內部人持股大部分。這意味着他們可以集體爲公司做出決策。也就是說,他們在總市值爲28億元的公司中擁有價值18億元的股份。這相當有意義。很高興看到這個投資水平。您可以在此處檢查這些內部人最近是否有買入。
To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.
爲了使我們的研究更有趣,我們發現前2名股東擁有該公司的大部分所有權,這意味着他們足夠強大,可以影響公司的決策。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
儘管研究一家公司的機構所有權可以爲您的研究增添價值,但研究分析師建議以深入了解股票的預期表現也是一個好的做法。我們的信息表明,該股票沒有任何分析師的覆蓋,因此可能爲人所知甚少。
Insider Ownership Of Harbin Medisan Pharmaceutical
似乎私人公司擁有4.0%的哈三聯製藥股票。僅憑這個事實很難得出任何結論,因此值得了解誰擁有那些私人公司。有時,內部人或其他相關方通過單獨的私人公司在公共公司中擁有股份。
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
內部人員的定義在不同國家可能略有不同,但董事會成員總是計入內部人員。管理層最終向董事會回答。然而,經理往往會成爲執行董事會成員,尤其是如果他們是創始人或CEO。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常認爲內部人士持股是一件好事。但是,在某些情況下,它會使其他股東更難以對董事會的決定進行問責。
Our most recent data indicates that insiders own the majority of Harbin Medisan Pharmaceutical Co., Ltd.. This means they can collectively make decisions for the company. That means they own CN¥1.8b worth of shares in the CN¥2.8b company. That's quite meaningful. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.
始終值得考慮擁有公司股份的不同群體。但是要更好地了解哈三聯製藥,我們需要考慮許多其他因素。就像風險一樣。每家公司都有其風險,我們已經發現哈三聯製藥有4個警告信號(其中3個相當重要!)你需要知道。
General Public Ownership
一般大衆所有權
The general public-- including retail investors -- own 29% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
儘管考慮不同擁有公司的團體是值得的,但有些因素更爲重要。例如,我們已經爲中國醫藥系統控股公司確定了2個警示信號,您應該注意到這些信號。
Private Company Ownership
私有公司的所有權
It seems that Private Companies own 4.0%, of the Harbin Medisan Pharmaceutical stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Harbin Medisan Pharmaceutical better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 4 warning signs for Harbin Medisan Pharmaceutical (of which 3 are significant!) you should know about.
始終值得考慮擁有公司股份的不同群體。但是要更好地了解哈三聯製藥,我們需要考慮許多其他因素。就像風險一樣。每家公司都有其風險,我們已經發現哈三聯製藥有4個警告信號(其中3個相當重要!)你需要知道。
Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.
當然,這可能不是最好的購買股票。因此,查看這份免費免費的有趣公司列表可能會有所幫助。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。